AUDENTES THERAPEUTICS
Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs. Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.
AUDENTES THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Health Diagnostics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.audentestx.com
Total Employee:
251+
Status:
Active
Contact:
+1 (415) 638-6556
Email Addresses:
[email protected]
Total Funding:
744.7 M USD
Technology used in webpage:
Domain Not Resolving Euro SPF Google Tag Manager Amazon Global Site Tag IPv6 JsDelivr Microsoft Exchange Online Office 365 Mail
Similar Organizations
Alector
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Freenome
Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Geneoscopy
Geneoscopy develops a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Invitae
Invitae is a medical genetics company that bring comprehensive genetic information into mainstream medicine to improve healthcare.
Orchard Therapeutics
Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
PathAI
PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Personalis
Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Prenetics
Prenetics is a genetic and diagnostic health testing company that helps to identify health risks with the use of DNA sequencing technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-09-01 | CardioGen Sciences | CardioGen Sciences acquired by Audentes Therapeutics | N/A |
Investors List
Envision Capital Management
Envision Capital Management investment in Post-IPO Equity - Audentes Therapeutics
Venrock
Venrock investment in Series C - Audentes Therapeutics
5AM Ventures
5AM Ventures investment in Series C - Audentes Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Audentes Therapeutics
Deerfield
Deerfield investment in Series C - Audentes Therapeutics
Redmile Group
Redmile Group investment in Series C - Audentes Therapeutics
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Series C - Audentes Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Audentes Therapeutics
OrbiMed
OrbiMed investment in Series C - Audentes Therapeutics
Foresite Capital
Foresite Capital investment in Series C - Audentes Therapeutics
Official Site Inspections
http://www.audentestx.com
- Host name: ec2-54-159-65-133.compute-1.amazonaws.com
- IP address: 54.159.65.133
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Audentes Therapeutics"
ABOUT US - Astellas Gene Therapies
Richard joined Astellas Gene Therapies (formerly Audentes Therapeutics) in April 2020 as Vice President, Program Management. Richard has over 30 years of experience in research, …See details»
Audentes Therapeutics - Crunchbase Company Profile & Funding
Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into …See details»
News - Astellas Pharma Inc.
TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 2, 2019-- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. …See details»
Astellas Completes Acquisition of Audentes Therapeutics
The acquisition positions the combined company to become a global leader in AAV-based genetic medicines. “The Audentes team is comprised of highly talented individuals with world-class …See details»
Audentes Therapeutics Information - RocketReach
Audentes Therapeutics is a Biotechnology, Education, and Pharmaceuticals company located in San Francisco, California with $6 million in revenue and 384 employees. Find top employees, …See details»
Astellas Completes Acquisition of Audentes Therapeutics
Jan 15, 2020 Astellas and Audentes have based these forward-looking statements on current expectations and projections about future events and trends that they believe may affect the financial condition, results of …See details»
AudentesTherapeutics - Company Profile - Tracxn
Feb 22, 2025 AudentesTherapeutics - Developer of therapeutics to treat rare genetic diseases. Acquired by Astellas Pharma. Raised a total funding of $138M over 3 rounds from 17 investors.See details»
Audentes Therapeutics - Company Profile & Staff Directory
Audentes Therapeutics, Inc., an Astellas company, is a leader in developing AAV-based genetic medicines with the potential to offer transformative benefits to patients. In addition to our …See details»
SEC.gov | HOME
Dec 3, 2019 We have a great deal of respect and admiration for your organization, the vision and the strategy you have set, and we look forward to the opportunities that will be created by …See details»
Astellas Gene Therapies Company Overview, Contact Details
Feb 22, 2024 Learn more about Astellas Gene Therapies's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
News - Astellas Pharma Inc.
Mar 31, 2021 New Center of Excellence created within Astellas expanding access to global resources and adding additional gene therapy research programs over time to develop and …See details»
Audentes Therapeutics Announces Expansion of AAV Technology …
Apr 8, 2019 Audentes Therapeutics announced that it is expanding its scientific platform and beginning development of new AAV-based genetic medicines for Duchenne. Audentes is a …See details»
Press Release - Astellas Pharma
Jan 15, 2020 The acquisition positions the combined company to become a global leader in AAV-based genetic medicines. “The Audentes team is comprised of highly talented individuals …See details»
Astellas Completes Acquisition of Audentes Therapeutics
Jan 15, 2020 Audentes Therapeutics, Inc., an Astellas company, is an AAV-based genetic medicines company focused on developing and commercializing innovative therapies that can …See details»
EX-99.2 - SEC.gov
Dec 3, 2019 Audentes is a leading Adeno-associated virus (AAV)-based genetic medicines company focused on developing and commercializing gene therapy products for serious and …See details»
EX-99.3 - SEC.gov
Audentes has based these forward-looking statements on current expectations and projections about future events and trends that it believes may affect the financial condition, results of …See details»
Audentes Therapeutics Announces Co-Founder and Chief …
Oct 3, 2018 The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives …See details»
Audentes Therapeutics and Genethon Announce Agreement to …
Promising preclinical data recently published in Science Translational Medicine SAN FRANCISCO, CA – February 5, 2014 –Audentes Therapeutics, Inc., a biotechnology company …See details»
Astellas Enters into Definitive Agreement to Acquire Audentes ...
Dec 2, 2019 - Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and …See details»
News - Astellas Pharma Inc.
Feb 18, 2020 - Audentes plans to invest over $100 million and create over 200 new jobs in Lee County SAN FRANCISCO, CA and RALEIGH, N.C., February 18, 2020/BUSINESSWIRE/ - …See details»